Boehringer Ingelheim's JASCAYD Nears EU Approval for IPF and PPF Treatment
Event summary
- CHMP recommends marketing authorization for JASCAYD® (nerandomilast) in the EU for IPF and PPF treatment.
- Positive opinion based on Phase III FIBRONEER™ trial results showing slowed lung function decline.
- JASCAYD® is the first preferential PDE4B inhibitor approved in the US, China, UAE, and Japan.
- Boehringer Ingelheim aims to address high unmet need in IPF and PPF, with over 500,000 affected in the EU.
The big picture
Boehringer Ingelheim's JASCAYD® represents a significant advancement in treating IPF and PPF, addressing a critical unmet need in pulmonary fibrosis. The CHMP's positive opinion underscores the growing demand for therapies with better tolerability and efficacy, potentially reshaping the treatment landscape for these life-threatening conditions. With over 500,000 affected individuals in the EU, the approval could mark a turning point in managing progressive lung diseases.
What we're watching
- Regulatory Approval
- Whether the EU approval will accelerate adoption in other regions under review.
- Market Penetration
- How Boehringer Ingelheim will position JASCAYD® against existing treatments with known limitations.
- Clinical Expansion
- The pace at which Boehringer Ingelheim advances nerandomilast for systemic sclerosis and myositis.
Related topics